Cargando…

Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide

The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been the focus of attention. Recently, letermovir (...

Descripción completa

Detalles Bibliográficos
Autores principales: Terao, Toshiki, Matsuoka, Ken-ichi, Narita, Kentaro, Tsushima, Takafumi, Yuyama, Satoshi, Kuzume, Ayumi, Tabata, Rikako, Miura, Daisuke, Takeuchi, Masami, Matsue, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117228/
https://www.ncbi.nlm.nih.gov/pubmed/33996594
http://dx.doi.org/10.3389/fonc.2021.666774
_version_ 1783691553563213824
author Terao, Toshiki
Matsuoka, Ken-ichi
Narita, Kentaro
Tsushima, Takafumi
Yuyama, Satoshi
Kuzume, Ayumi
Tabata, Rikako
Miura, Daisuke
Takeuchi, Masami
Matsue, Kosei
author_facet Terao, Toshiki
Matsuoka, Ken-ichi
Narita, Kentaro
Tsushima, Takafumi
Yuyama, Satoshi
Kuzume, Ayumi
Tabata, Rikako
Miura, Daisuke
Takeuchi, Masami
Matsue, Kosei
author_sort Terao, Toshiki
collection PubMed
description The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been the focus of attention. Recently, letermovir (LTV) was approved for preventing cytomegalovirus (CMV) reactivation in the early transplantation phase. Although CMV affects the immune reconstitution after HSCT, the impacts of LTV to prevent CMV reactivation on early T-cell recovery and cGVHD have not been fully investigated. We aimed to identify early T-cell recovery under LTV at day 30 in 15 and 33 recipients from matched related donors (MRDs) and haploidentical donors with post-transplant cyclophosphamide (PTCy-haplo), respectively. Early increases in the levels of total lymphocytes and HLA-DR(+) activated T-cells at day 30 were observed under CMV prophylaxis by LTV only in PTCy-haplo recipients and not in MRD recipients. Moreover, PTCy-haplo recipients with LTV showed a significantly higher incidence of cGVHD, but not acute GVHD. Our observations suggest that an early increase in the levels of HLA-DR(+) activated T-cells may be implicated in the development of cGVHD in patients treated with PTCy who received LTV. Further studies are warranted to validate our results and elucidate the detailed mechanisms of our new insights.
format Online
Article
Text
id pubmed-8117228
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81172282021-05-14 Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide Terao, Toshiki Matsuoka, Ken-ichi Narita, Kentaro Tsushima, Takafumi Yuyama, Satoshi Kuzume, Ayumi Tabata, Rikako Miura, Daisuke Takeuchi, Masami Matsue, Kosei Front Oncol Oncology The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been the focus of attention. Recently, letermovir (LTV) was approved for preventing cytomegalovirus (CMV) reactivation in the early transplantation phase. Although CMV affects the immune reconstitution after HSCT, the impacts of LTV to prevent CMV reactivation on early T-cell recovery and cGVHD have not been fully investigated. We aimed to identify early T-cell recovery under LTV at day 30 in 15 and 33 recipients from matched related donors (MRDs) and haploidentical donors with post-transplant cyclophosphamide (PTCy-haplo), respectively. Early increases in the levels of total lymphocytes and HLA-DR(+) activated T-cells at day 30 were observed under CMV prophylaxis by LTV only in PTCy-haplo recipients and not in MRD recipients. Moreover, PTCy-haplo recipients with LTV showed a significantly higher incidence of cGVHD, but not acute GVHD. Our observations suggest that an early increase in the levels of HLA-DR(+) activated T-cells may be implicated in the development of cGVHD in patients treated with PTCy who received LTV. Further studies are warranted to validate our results and elucidate the detailed mechanisms of our new insights. Frontiers Media S.A. 2021-04-29 /pmc/articles/PMC8117228/ /pubmed/33996594 http://dx.doi.org/10.3389/fonc.2021.666774 Text en Copyright © 2021 Terao, Matsuoka, Narita, Tsushima, Yuyama, Kuzume, Tabata, Miura, Takeuchi and Matsue https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Terao, Toshiki
Matsuoka, Ken-ichi
Narita, Kentaro
Tsushima, Takafumi
Yuyama, Satoshi
Kuzume, Ayumi
Tabata, Rikako
Miura, Daisuke
Takeuchi, Masami
Matsue, Kosei
Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title_full Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title_fullStr Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title_full_unstemmed Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title_short Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
title_sort letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117228/
https://www.ncbi.nlm.nih.gov/pubmed/33996594
http://dx.doi.org/10.3389/fonc.2021.666774
work_keys_str_mv AT teraotoshiki letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT matsuokakenichi letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT naritakentaro letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT tsushimatakafumi letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT yuyamasatoshi letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT kuzumeayumi letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT tabatarikako letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT miuradaisuke letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT takeuchimasami letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide
AT matsuekosei letermoviradministrationtopreventcytomegalovirusreactivationisthepotentialriskofchronicgraftversushostdiseaseinpatientswhoreceivedhaploidenticalstemcelltransplantationwithposttransplantcyclophosphamide